Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
IrelandIPO:
25 June 2021Website:
http://www.ghres.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 01 Nov 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
GHRS Latest News
GH Research (GHRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
GH Research (GHRS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
DUBLIN, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2024, and provided updates on its business.
GH Research (GHRS) is a strong stock that has caught the attention of investors seeking to capitalize on stocks showing recent price strength.
The average of price targets set by Wall Street analysts indicates a potential upside of 321.3% in GH Research PLC (GHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
What type of business is GH Research?
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
What sector is GH Research in?
GH Research is in the Healthcare sector
What industry is GH Research in?
GH Research is in the Biotechnology industry
What country is GH Research from?
GH Research is headquartered in Ireland
When did GH Research go public?
GH Research initial public offering (IPO) was on 25 June 2021
What is GH Research website?
https://www.ghres.com
Is GH Research in the S&P 500?
No, GH Research is not included in the S&P 500 index
Is GH Research in the NASDAQ 100?
No, GH Research is not included in the NASDAQ 100 index
Is GH Research in the Dow Jones?
No, GH Research is not included in the Dow Jones index
When was GH Research the previous earnings report?
No data
When does GH Research earnings report?
The next expected earnings date for GH Research is 08 November 2024